Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AstraZeneca's ADC disappoints - on severe adverse events

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 23, 2024 4:56pm

65 Views

Post# 36237177

RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

September 23, 2023 - AstraZeneca, Daiichi’s Enhertu successor faces more questions after latest stumble

The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, fueling doubts about its approval prospects.

But the future of datopotomab deruxtecan, or dato-dxd for short, is now unclear. In lung cancer, it similarly delayed disease progression in a Phase 3 trial, but didn't extend survival, even among those who had been expected to benefit the most from treatment. That result, which was disclosed earlier this month, led analysts at the investment bank Stifel to speculate that the FDA might delay an approval decision and convene a panel of outside advisers.

Dato-dxd could now face a more complex path to market in breast cancer too. Overall survival was one of the two main goals of its breast cancer trial and is the FDA’s gold standard for the approval of a cancer drug.